Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek M Rangnekar

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Cancer Biology & Therapy|August 13, 2002
Art of excellence in scientific researchVivek M Rangnekar
Cancer Biology & Therapy|May 24, 2005
Exploiting the TSA connections to overcome apoptosis-resistancePadhma Ranganathan, Vivek M Rangnekar
Current Drug Targets|March 20, 2003
Par-4 for molecular therapy of prostate cancerJames Butler, Vivek M Rangnekar
Annals of the New York Academy of Sciences|December 31, 2005
Regulation of cancer cell survival by Par-4Padhma Ranganathan, Vivek M Rangnekar
Journal of Cellular Biochemistry|February 3, 2004
Par-4 inducible apoptosis in prostate cancer cellsSushma Gurumurthy, Vivek M Rangnekar
Cancer Biology & Therapy|December 23, 2009
Targeting plasma membrane GRP78 for cancer growth inhibitionSteve Schwarze, Vivek M Rangnekar
Cancer Biology & Therapy|October 7, 2008
Apoptosis and tumor resistance conferred by Par-4Yanming Zhao, Vivek M Rangnekar
Experimental Cell Research|February 5, 2003
Apoptosis by Par-4 in cancer and neurodegenerative diseasesNadia El-Guendy, Vivek M Rangnekar
Current Pharmaceutical Design|February 18, 2004
Molecular therapy intervention prospects in prostate cancerYashraj D Rege, Vivek M Rangnekar
Cancer Biology & Therapy|February 1, 2007
"D" approach to prevent metastasisLucia R Languino, Vivek M Rangnekar
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Cancer Biology & Therapy|August 13, 2002
Art of excellence in scientific researchVivek M Rangnekar
Cancer Biology & Therapy|May 24, 2005
Exploiting the TSA connections to overcome apoptosis-resistancePadhma Ranganathan, Vivek M Rangnekar
Current Drug Targets|March 20, 2003
Par-4 for molecular therapy of prostate cancerJames Butler, Vivek M Rangnekar
Annals of the New York Academy of Sciences|December 31, 2005
Regulation of cancer cell survival by Par-4Padhma Ranganathan, Vivek M Rangnekar
Journal of Cellular Biochemistry|February 3, 2004
Par-4 inducible apoptosis in prostate cancer cellsSushma Gurumurthy, Vivek M Rangnekar
Cancer Biology & Therapy|December 23, 2009
Targeting plasma membrane GRP78 for cancer growth inhibitionSteve Schwarze, Vivek M Rangnekar
Cancer Biology & Therapy|October 7, 2008
Apoptosis and tumor resistance conferred by Par-4Yanming Zhao, Vivek M Rangnekar
Experimental Cell Research|February 5, 2003
Apoptosis by Par-4 in cancer and neurodegenerative diseasesNadia El-Guendy, Vivek M Rangnekar
Current Pharmaceutical Design|February 18, 2004
Molecular therapy intervention prospects in prostate cancerYashraj D Rege, Vivek M Rangnekar
Cancer Biology & Therapy|February 1, 2007
"D" approach to prevent metastasisLucia R Languino, Vivek M Rangnekar
Pageof 8